Literature DB >> 15447813

Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response.

Sylvie Lemonde1, Lisheng Du, David Bakish, Pavel Hrdina, Paul R Albert.   

Abstract

Antidepressants, such as serotonin or noradrenaline reuptake inhibitors (e.g. fluoxetine, nefadozone) or 5-HT1A agonists (flibanserin), desensitize the 5-HT1A autoreceptor, which may contribute to their clinical efficacy. The 5-HT1A receptor gene is repressed by NUDR/DEAF-1 in raphe cells at the C-, but not at the G-allele of the C(-1019)G polymorphism that is associated with major depression and suicide. Depressed patients (n=118) were treated with antidepressants including fluoxetine or nefadozone combined with pindolol or flibanserin alone. The severity of depression was assesssed using the Hamilton Rating Scale for Depression. Although patients had similar severity initially, those with the homozygous G(-1019) genotype responded significantly less to flibanserin (p=0.039) and in pooled antidepressant treatment groups (p=0.0497) and were approximately twice as likely to be non-responders as those with the C(-1019)C genotype. These results implicate the C(-1019)G 5-HT1A gene polymorphism as a potential marker for antidepressant response, suggesting a role for repression of the 5-HT1A gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15447813     DOI: 10.1017/S1461145704004699

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  56 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635.

Authors:  Eydie L Moses-Kolko; Julie C Price; Michael E Thase; Carolyn Cidis Meltzer; David J Kupfer; Chester A Mathis; Wendy D Bogers; Susan R Berman; Patricia R Houck; Trisha N Schneider; Wayne C Drevets
Journal:  Synapse       Date:  2007-07       Impact factor: 2.562

Review 3.  5-HT(1A) receptor function in major depressive disorder.

Authors:  Jonathan Savitz; Irwin Lucki; Wayne C Drevets
Journal:  Prog Neurobiol       Date:  2009-02-07       Impact factor: 11.685

4.  Pharmacogenetics of antidepressive treatment.

Authors:  Astrid Zobel; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-01-03       Impact factor: 5.270

Review 5.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

6.  Does the 5-HT1A rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?

Authors:  Greg Scutt; Andrew Overall; Railton Scott; Bhavik Patel; Lamia Hachoumi; Mark Yeoman; Juliet Wright
Journal:  Ther Adv Drug Saf       Date:  2018-04-23

7.  Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness.

Authors:  Gary M Levin; Toya M Bowles; Megan J Ehret; Taimour Langaee; Jennifer Y Tan; Julie A Johnson; William J Millard
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 8.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

9.  Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder.

Authors:  Bernadeta Szewczyk; Paul R Albert; Ariel M Burns; Margaret Czesak; James C Overholser; George J Jurjus; Herbert Y Meltzer; Lisa C Konick; Lesa Dieter; Nicole Herbst; Warren May; Grazyna Rajkowska; Craig A Stockmeier; Mark C Austin
Journal:  Int J Neuropsychopharmacol       Date:  2008-06-19       Impact factor: 5.176

10.  Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.

Authors:  Matthew S Milak; Ramin V Parsey; Leilani Lee; Maria A Oquendo; Doreen M Olvet; Francoise Eipper; Kevin Malone; J John Mann
Journal:  Psychiatry Res       Date:  2009-05-14       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.